Aktuelle smitsomme sygdomme
Søgeord (prep) valgt.
7 emner vises.
Florian Gehre, Eric Nzeyimana, Hakim Idris Lagu, Emmanuel Achol, Julien A Nguinkal, Eric Kezakarayagwa, Théogene Ihorimbere, Néhémie Nzoyikorera, Francine Kabatesi, Marie-Noelle Uwineza, Abdi Roba, Millicent Nyakio Ndia, John Ndemi Kiiru, Gwokpan Awin Nykwec, Isaac Gatkuoth Chot Moun, Mamdouh A Aguer, James A Maror, Gregory Wani Dumo, Michael Losuba, Lul Lojok Deng, Neema Omari, Grace Ochido, Aryse Martins Melo, Peter Bernard Mtesigwa Mkama, Edna Mgimba, Monica Fredrick Francis, Lawrence A Mapunda, Alex Magesa, Nyambura Moremi, Godfrey Pimundu, Tonny Muyigi, Susan Ndidde Nabadda, Emmanuel Kabalisa, Isabelle Mukagatare, Daniel Mukadi-Bamuleka, Erick Ntambwe Kamangu, Jürgen May and Muna Affara
Eurosurveillance latest updates, 30.08.2024
Tilføjet 30.08.2024
The East African Community (EAC) is experiencing an unprecedented, emerging mpox outbreak since July 2024 in five of eight partner states. We highlight rapid regional response measures, initiated August 2024 coordinated by EAC: field deployment of six mobile laboratories in Burundi, Rwanda, Uganda, Tanzania, Kenya, South Sudan to high-risk areas, donation of one mobile laboratory to Democratic Republic of the Congo and genomic monkeypox virus (MPXV) surveillance support. These interventions aim to limit local mpox spread and support international containment.
Læs merePhillip Zucs, Julien Beauté, Daniel Palm and Gianfranco Spiteri
Eurosurveillance latest updates, 23.08.2024
Tilføjet 23.08.2024
This perspective summarises and explains the long-term surveillance framework 2021–2027 for infectious diseases in the European Union/European Economic Area (EU/EEA) published in April 2023. It shows how shortcomings in the areas of public health focus, vigilance and resilience will be addressed through specific strategies in the coming years and how these strategies will lead to stronger surveillance systems for early detection and monitoring of public health threats as well as informing their effective prevention and control. A sharper public health focus is expected from a more targeted list of notifiable diseases, strictly public-health-objective-driven surveillance standards, and consequently, leaner surveillance systems. Vigilance should improve through mandatory event reporting, more automated epidemic intelligence processing and increased use of genomic surveillance. Finally, EU/EEA surveillance systems should become more resilient by modernising the underlying information technology infrastructure, expanding the influenza sentinel surveillance system to other respiratory viruses for better pandemic preparedness, and increasingly exploiting potentially more robust alternative data sources, such as electronic health records and wastewater surveillance. Continued close collaboration across EU/EEA countries will be key to ensuring the full implementation of this surveillance framework and more effective disease prevention and control.
Læs mereMedscape Infectious Diseases, 22.08.2024
Tilføjet 22.08.2024
Preexposure prophylaxis prescription reversals and abandonments were lower for patients seen by primary care clinicians than by other noninfectious disease clinicians. MDedge News
Læs mereMedscape Infectious Diseases, 25.07.2024
Tilføjet 25.07.2024
Final results of the highly anticipated PURPOSE 1 trial of lenacapavir show the shots prevent new infections without many side effects. Medscape Medical News
Læs mereLouise Marron, Alberto Mateo-Urdiales, Joan O’Donnell, Eve Robinson and Lisa Domegan
Eurosurveillance latest updates, 12.07.2024
Tilføjet 12.07.2024
BackgroundAs Ireland prepared for an autumn 2023 COVID-19 vaccination booster campaign, there was concern that vaccine fatigue would affect uptake, which has been abating. AimThis study aimed to quantify the direct impact of the COVID-19 vaccination programme in Ireland on averted COVID-19-related outcomes including symptomatic presentations to primary care/community testing centres, emergency department (ED) presentations, hospitalisations, intensive care unit (ICU) admissions and deaths, in individuals aged ≥ 50 years, during Omicron dominance. MethodsWe conducted a retrospective observational COVID-19 vaccine impact study in December 2021–March 2023 in Ireland. We used national data on notified outcomes and vaccine coverage, as well as vaccine effectiveness (VE) estimates, sourced from the World Health Organization’s live systematic review of VE, to estimate the count and prevented fraction of outcomes in ≥ 50-year-olds averted by the COVID-19 vaccination programme in this age group. ResultsThe COVID-19 vaccination programme averted 48,551 symptomatic COVID-19 presentations to primary care/community testing centres (36% of cases expected in the absence of vaccination), 9,517 ED presentations (53% of expected), 102,160 hospitalisations (81% of expected), 3,303 ICU admissions (89% of expected) and 15,985 deaths (87% of expected). ConclusionsWhen Omicron predominated, the COVID-19 vaccination programme averted symptomatic and severe COVID-19 cases, including deaths due to COVID-19. In line with other international vaccine impact studies, these findings emphasise the benefits of COVID-19 vaccination for population health and the healthcare system and are relevant for informing COVID-19 booster vaccination programmes, pandemic preparedness and communicating the reason for and importance of COVID-19 vaccination in Ireland and internationally.
Læs mereMedscape Infectious Diseases, 5.07.2024
Tilføjet 5.07.2024
Patients at a high risk for HIV infection who received preexposure prophylactic injections with lenacapavir had 100% efficacy in a phase 3 clinical trial. Medscape Medical News
Læs mereMaaike C Swets, Annabel Niessen, Emilie P Buddingh, Ann CTM Vossen, Karin Ellen Veldkamp, Irene K Veldhuijzen, Mark GJ de Boer and Geert H Groeneveld
Eurosurveillance latest updates, 5.07.2024
Tilføjet 5.07.2024
BackgroundEffective pandemic preparedness requires robust severe acute respiratory infection (SARI) surveillance. However, identifying SARI patients based on symptoms is time-consuming. Using the number of reverse transcription (RT)-PCR tests or contact and droplet precaution labels as a proxy for SARI could accurately reflect the epidemiology of patients presenting with SARI. AimWe aimed to compare the number of RT-PCR tests, contact and droplet precaution labels and SARI-related International Classification of Disease (ICD)-10 codes and evaluate their use as surveillance indicators. MethodsPatients from all age groups hospitalised at Leiden University Medical Center between 1 January 2017 up to and including 30 April 2023 were eligible for inclusion. We used a clinical data collection tool to extract data from electronic medical records. For each surveillance indicator, we plotted the absolute count for each week, the incidence proportion per week and the correlation between the three surveillance indicators. ResultsWe included 117,404 hospital admissions. The three surveillance indicators generally followed a similar pattern before and during the COVID-19 pandemic. The correlation was highest between contact and droplet precaution labels and ICD-10 diagnostic codes (Pearson correlation coefficient: 0.84). There was a strong increase in the number of RT-PCR tests after the start of the COVID-19 pandemic. DiscussionAll three surveillance indicators have advantages and disadvantages. ICD-10 diagnostic codes are suitable but are subject to reporting delays. Contact and droplet precaution labels are a feasible option for automated SARI surveillance, since these reflect trends in SARI incidence and may be available real-time.
Læs mere